Search for Clinical Trial Results

Sponsored By

Leiomyosarcoma - 29 Studies Found

Status Study
Completed Study Name: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Condition:
  • Recurrent Uterine Corpus Sarcoma
  • Uterine Corpus Leiomyosarcoma<
    Date: 2002-03-08
    Interventions:
    • Drug: Docetaxel Given IV
Completed Study Name: Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Condition:
  • Leiomyosarcoma
  • Liposarcoma

Date: 2011-08-29
Interventions: Drug: Gemcitabine + Trabectedin Combination therapy of gemcitabine and trabectedin
Completed Study Name: A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Condition:
  • Liposarcoma
  • Leiomyosarcoma

Date: 2003-05-16
Interventions:
  • Drug: Yondelis 1.5 mg/m2 admin
Completed Study Name: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Condition: Locally Advanced Uterine Corpus Leiomyosarcoma
Date: 2025-08-02
Interventions: Undergo collection of blood samples
Completed Study Name: Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
Condition: Leiomyosarcoma
Date: 2025-08-02
Interventions: Intravenous Infusion
Completed Study Name: Localized Leiomyosarcoma Biomarker Protocol
Condition: Leiomyosarcoma
Date: 2025-08-02
Interventions: Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
COMPLETED Study Name: Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
Condition: Leiomyosarcoma
Date: 2025-08-02
Interventions: Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
COMPLETED Study Name: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Condition: Leiomyosarcoma
Date: 2025-08-02
Interventions: Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
COMPLETED Study Name: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Condition: Leiomyosarcoma
Date: 2025-08-02
Interventions: Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
<<< Previous